Prosecution Insights
Last updated: April 19, 2026
Application No. 17/968,327

Hypodermic Interface Assembly

Final Rejection §103
Filed
Oct 18, 2022
Examiner
SCHMIDT, EMILY LOUISE
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Neogen Corporation
OA Round
2 (Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
3y 5m
To Grant
95%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allow Rate
581 granted / 992 resolved
-11.4% vs TC avg
Strong +36% interview lift
Without
With
+36.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
77 currently pending
Career history
1069
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
48.9%
+8.9% vs TC avg
§102
25.8%
-14.2% vs TC avg
§112
18.7%
-21.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 992 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 16/947,305, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. The prior filed application does not disclose a core. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-10 and 12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Monson et al. (US 2009/0312715 A1) in view of Schraga (US 2012/0123334 A1). With regard to claims 1-9 and 12, Monson et al. teach a hypodermic interface assembly comprising: a hub having a distal end surface (Fig. 5 member 40); a core member define by a body having a proximal end surface and a distal end surface (Fig. 5 portion around 82 within 86, has a body, proximal and distal ends, a passage, and is received by and extends beyond the carrier); a cannula, wherein a portion of the cannula extends in a distal direction from the distal end surface of the hub and in a proximal direction from the proximal end surface of the body of the core member (Fig. 4 member 82 extends through the hub, core, and carrier and beyond, Fig. 5 one portion non removably connected to the core, the cannula necessarily extends between the portion extending distally of the hub and proximally of the core, Fig. 5 one portion non removably connected to the core and one portion spaced from the carrier); and a cannula carrier having a head portion (Fig. 5 member 86, head in the area of 89), and wherein the cannula carrier is controllably separable from the hub (Fig. 5). Monson et al. do not teach the carrier to have a plurality of leg portions. However, Schraga teaches a threaded cannula carrier which has a plurality of legs which flex outwardly to allow the carrier to be threaded onto the injector as well as inserted and removed in additional fashions which do not include rotation and may enhance safety (Figs. 11- 14 slots 16’’’ form legs which are connected via frangible portions which break when subjected to force to separate the legs from the hub, this would be capable of occurring depending on the force and movement from the subject [0005], [0079], [0081], [0082], [0085], [0086]). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to use a plurality of legs which can deflect radially outward in response to a radial force in Monson et al. as Schraga teaches this is beneficial for connecting the cannula carrier in a plurality of manners to enhance safety. Monson et al. do not explicitly recite how the core and cannula and the carrier and core are attached. However, Monson et al. teach various connections include adhesives or press-fit ([0020], [0027]). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to use a press-fit connection between the components of Monson et al. as Monson et al. teach such is an art effective connection means to prevent movement and would yield the same predictable result. With regard to claim 10, See Fig. 4 the proximal end of the carrier is adjacent a shoulder of the hub generally in the area of 46, as combined this is where the proximal end of the leg surface would be located. Claim(s) 13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Monson et al. (US 2009/0312715 A1) as applied to claim 12 above, and further in view of Bennwik et al. (US 5,709,659). With regard to claim 13, Monson et al. teach a device substantially as claimed. In Monson et al. member 97 is also considered as part of the hub which has a distal end surface that is spaced from the core. Monson et al. do not disclose the cannula is configured to bend or break. However, Bennwik et al. teach permanently detaching the carrier from the hub of a syringe to break the needle to prevent reuse (abstract, Figs. 5). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to configure the cannula of Monson et al. to break as in Bennwik et al. as this is beneficial for preventing re-use. Claim(s) 14-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Monson et al. (US 2009/0312715 A1) in view of Zhao (US 2012/0150128 A1). With regard to claims 14, 20, and 21, Monson et al. teach a subassembly of a hypodermic interface assembly, the subassembly comprising: a hub having a distal end surface (Fig. 5 member 86); a core member having a body defined by a proximal end surface and a distal end surface (Fig. 5 portion around 82 within 86); and a cannula connected to the core member and the hub such that the cannula is not permitted to axially shift relative to the core member or the hub (Fig. 4 member 82, extends through a passage in the core), wherein a portion of the cannula extends in a distal direction from the distal end surface of the hub and in a proximal direction from the proximal end surface of the body of the core member (Fig. 5). Monson et al. do not explicitly recite how the core, cannula, and hub are attached. However, Monson et al. teach various connections include adhesives or press-fit ([0020], [0027]). Further, Zhao teaches adhesive may be used to secure a cannula within a core and hub and to secure a core to a hub (Fig. 4, adhesive secure core 44 to a hub, [0024]). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to non-removably connect the components of Monson et al. as Zhao teach such to be an art effective connection means for fixation and Monson et al. teach such is an art effective connection means to prevent movement and would yield the same predictable result. With regard to claim 15, see Fig. 5. With regard to claims 16 and 17, distance necessarily exists, see Reference Figure 1 below. PNG media_image1.png 341 410 media_image1.png Greyscale With regard to claim 18, see the differing passage diameter at the distal end (Fig. 5). With regard to claim 19, see the outer diameter at the proximal end of the core which is smaller (Fig. 5). Allowable Subject Matter Claim 11 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Response to Arguments Applicant’s arguments with respect to the claim(s) have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. The newly amended limitations are addressed as above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EMILY L SCHMIDT whose telephone number is (571)270-3648. The examiner can normally be reached Monday through Thursday 7:00 AM to 4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin Sirmons can be reached at 571-272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EMILY L SCHMIDT/ Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Oct 18, 2022
Application Filed
Mar 11, 2024
Response after Non-Final Action
Nov 03, 2025
Non-Final Rejection — §103
Feb 03, 2026
Examiner Interview Summary
Feb 03, 2026
Applicant Interview (Telephonic)
Feb 04, 2026
Response Filed
Mar 09, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599750
VASCULAR ACCESS CONNECTOR SUPPORT DEVICE, SYSTEMS, AND METHODS
2y 5m to grant Granted Apr 14, 2026
Patent 12576214
BUTTON AND BUTTON ASSEMBLY FOR A DRUG DELIVERY DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12569625
RIGID NEEDLE SHIELD REMOVER WITH DROP TEST FEATURE FOR AUTOINJECTOR
2y 5m to grant Granted Mar 10, 2026
Patent 12544516
Ultra-Low Waste Disposable Syringe with Self-Adjusting Integrated Safety Features
2y 5m to grant Granted Feb 10, 2026
Patent 12502482
COLLAR CAM LOCK FOR INJECTION DEVICES
2y 5m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
95%
With Interview (+36.0%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 992 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month